



GUIDELINES

Take Home Naloxone Pilot

August 2020



Australian Government
Department of Health

TAKE HOME NALOXONE PILOT

1	INTRODUCTION	3
2	BACKGROUND	3
3	PARTICIPATION	3
3.1	Community (s90) pharmacies, hospital (s94) pharmacies and approved (s92) medical practitioners.....	4
3.2	Authorised Alternative Suppliers	4
3.3	Wholesalers	4
3.4	Individuals receiving naloxone.....	5
4	DATA SUBMISSION	5
5	FEES	6
6	FUNDING AVAILABILITY	8
7	REGISTRATION	8
8	AUDIT REQUIREMENTS	8
9	REVIEW OF DECISIONS	8
APPENDIX A	DATA COLLECTION FOR THE SUPPLY OF NALOXONE TO INDIVIDUALS	9
APPENDIX B	DATA COLLECTION FOR THE BULK SUPPLY OF NALOXONE TO AAS	11
APPENDIX C	PREVIOUS SUPPLY FEES	12

TAKE HOME NALOXONE PILOT

LIST OF TABLES

Table 5-1: Naloxone supply fees: Community (S90) Pharmacies	6
Table 5-2: Naloxone supply fees: Public Hospital (S94) Pharmacies	6
Table 5-3: Naloxone supply fees: Private Hospital (S94) Pharmacies	7
Table 5-4: Naloxone supply fees: Approved Medical Practitioners (S92)	7
Table 5-5: Naloxone supply fees: Manufacturers and Wholesalers	7
Table 8-1: Naloxone supply fees: Community (S90) Pharmacies	12
Table 8-2: Naloxone supply fees: Public Hospital (S94) Pharmacies	12
Table 8-3: Naloxone supply fees: Private Hospital (S94) Pharmacies	13
Table 8-4: Naloxone supply fees: Approved Medical Practitioners (S92)	13
Table 8-5: Naloxone supply fees: Manufacturers and Wholesalers	13
Table 9-6: Previous Naloxone supply fees: Community (S90) Pharmacies.....	14
Table 9-7: Previous Naloxone supply fees: Public Hospital (S94) Pharmacies	14
Table 9-8: Previous Naloxone supply fees: Private Hospital (S94) Pharmacies.....	15
Table 9-9: Previous Naloxone supply fees: Approved Medical Practitioners (S92).....	15
Table 9-10: Previous Naloxone supply fees: Manufacturers and Wholesalers.....	15

1 INTRODUCTION

This document contains the guidelines for Approved Providers participating in the Take Home Naloxone (THN) pilot.

2 BACKGROUND

Naloxone is a drug that reverses the effects of an opioid overdose. It can be injected or delivered through a nasal spray. In the THN pilot, naloxone is available free to people who are at risk of, or who may witness, an opioid overdose. No prescription is required. Funded by the Australian Government, the pilot is running between 1 December 2019 and 28 February 2021, in New South Wales, South Australia and Western Australia.

The pilot is being evaluated by the Institute for Social Science Research, University of Queensland.

3 PARTICIPATION

Each participating state (New South Wales, South Australia and Western Australia) will identify where naloxone will be available as part of the pilot. Approved Providers under the pilot are community pharmacies, hospital-based pharmacies and approved medical practitioners, who will be reimbursed for supplying naloxone under the pilot by the PPA.

Organisations such as alcohol and other drug treatment services, injecting centres, and homelessness/outreach services can also become a Provider by first becoming an **Authorised Alternative Supplier**. Information about registering to become an Authorised Alternative Supplier can be found [here](#).

TAKE HOME NALOXONE PILOT

3.1 Community (s90) pharmacies, hospital (s94) pharmacies and approved (s92) medical practitioners

To be eligible to participate in the THN pilot, and supply naloxone under the pilot, Approved Providers must:

- Be approved under sections 90, 92 or 94 of the *National Health Act 1953*
- Register for the THN pilot via the Pharmacy Programs Administrator [Portal](#)
- Confirm that they are registered for GST
- Agree the pharmacy/practice trading name and location may be listed on the Department of Health's pilot website and/or provided to participating state health departments for communications relating to the pilot
- Agree to provide services in accordance with these THN Pilot Guidelines, including the collection of required **payment** and **evaluation** data.

Pharmacies and approved medical practitioners are required to source naloxone through their usual supply channel (e.g. pharmaceutical wholesaler). Once naloxone has been supplied free of charge to an individual under the THN Pilot, a claim for payment can be made via the PPA portal. Claiming processes for naloxone dispensed over the counter, or on PBS or private script do not change.

3.2 Authorised Alternative Suppliers

To be eligible to participate in the THN pilot, and supply naloxone under the pilot, an Approved Alternative Supplier must:

- Be approved by the relevant state health authority to provide naloxone under the THN Pilot Program
- Agree to provide services in accordance with these THN Pilot Guidelines, including the collection of required **evaluation** data.

Some AAS will also be required to register for the THN pilot via the Pharmacy Programs Administrator [Portal](#) and provide evaluation data directly to the PPA. These AAS are:

- Government AAS in New South Wales
- Certain AAS in South Australia.

AAS are required to source naloxone through a variety of mechanisms, depending on their location and should discuss these arrangements with their relevant state health authority. Information on who to contact can be found [here](#).

3.3 Wholesalers

To be eligible to participate in the THN pilot, and receive payments for naloxone supplied under the pilot, the wholesaler must:

- Have an arrangement in place with the Commonwealth Government to supply naloxone to AAS under the THN Pilot Program
- Register for the THN pilot via the Pharmacy Programs Administrator [Portal](#)
- Confirm that it is registered for GST

TAKE HOME NALOXONE PILOT

- Agree to provide services in accordance with these THN Pilot Guidelines, including the collection of required bulk supply **payment** data.

3.4 Individuals receiving naloxone

Anyone in NSW, SA or WA is able to access free naloxone under the pilot.

Specifically, the pilot aims to make naloxone free and easily available for:

- People who are at risk of an overdose, which includes illicit drug users and people who use prescription opioid medications
- Carers, friends, family and community.

4 DATA SUBMISSION

All Providers under the THN pilot are required to submit data, in most instances to the Pharmacy Programs Administrator, for claiming and/or evaluation purposes.

Two types of data are to be collected:

- Data required for making **payment**
- Additional data required for pilot **evaluation** purposes.

Payment data can relate to supplies of both naloxone to individuals, as well as the supply of bulk quantities of naloxone to AAS. The additional **evaluation data** relates to the supply of naloxone to individuals and is being collected on behalf of the Institute for Social Science Research, University of Queensland, who are completing an evaluation of the THN Pilot.

All Providers must discuss with the individual whether they consent to provide information for evaluation purposes, using the [Participant Information Statement](#) as a guide.

The data your organisation must collect depends on the type of supply (individual or bulk) and your location. The requirements for the submission of eligible claims are shown at:

- **Appendix A – Individual claims**, relevant for:
 - Community (s90) pharmacies
 - Public and Private Hospital (s94) pharmacies
 - Approved medical practitioners (s92)
 - AAS.
- **Appendix B - Bulk claims**, relevant for:
 - Wholesalers
 - Some public (s94) hospital pharmacies in NSW
 - Some private (s94) hospital pharmacies in SA.

TAKE HOME NALOXONE PILOT

5 FEES

The following tables contain the fees (including dispensing fee, where applicable) that are payable to each applicable Approved Provider by the Pharmacy Programs Administrator, for eligible claims made in relation to the supply of naloxone under the THN pilot from 1 July 2020. GST will be added to all supplies. The fees payable for supplies between 1 December 2019 and 30 June 2020 are available at Appendix C. Alternative Approved Suppliers do not receive fees for supplying naloxone.

Please note on 27 August 2020 Junalox was added to the list of products available to claim under the THN pilot.

Table 5-1: Naloxone supply fees: Community (S90) Pharmacies

Individual Supply (ex GST)	Product
\$48.96	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$41.88	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$45.88	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$45.88	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)
\$45.88	Junalox (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

Table 5-2: Naloxone supply fees: Public Hospital (S94) Pharmacies

Individual Supply (ex GST)	Bulk Supply (ex GST)	Product
\$36.94	\$34.36	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$29.86	\$27.77	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$33.86	\$31.49	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$33.86	\$31.49	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)
\$33.86	\$31.49	Junalox (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

TAKE HOME NALOXONE PILOT
Table 5-3: Naloxone supply fees: Private Hospital (S94) Pharmacies

Individual Supply (ex GST)	Bulk Supply (ex GST)	Product
\$45.20	\$34.36	Nyxoid (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$38.02	\$27.77	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$42.07	\$31.49	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$42.07	\$31.49	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)
\$42.07	\$31.49	Junalox (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)

Table 5-4: Naloxone supply fees: Approved Medical Practitioners (S92)

Individual Supply (ex GST)	Product
\$48.96	Nyxoid (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$41.88	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$45.88	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$45.88	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)
\$45.88	Junalox (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)

Table 5-5: Naloxone supply fees: Manufacturers and Wholesalers

Bulk Supply (ex GST)	Product
\$34.36	Nyxoid (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$27.77	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$31.49	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)

TAKE HOME NALOXONE PILOT

Bulk Supply (ex GST)	Product
\$31.49	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)
\$31.49	Junalox (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)

6 FUNDING AVAILABILITY

The Australian Government is investing \$10 million in the THN pilot, which is running between 1 December 2019 and 28 February 2021.

7 REGISTRATION

To become a Provider in the THN pilot, pharmacies, approved medical practitioners, wholesalers and some AAS (those allowed to supply naloxone in SA and Government AAS in NSW) must register via the Pharmacy Programs Administrator [Portal](#).

Registration will not be complete until the Provider receives email notification from the Pharmacy Programs Administrator confirming that registration has been successful.

8 AUDIT REQUIREMENTS

By participating in the program, organisations recognise that providing false or misleading information is a serious offence and auditing of claims made under the Program may occur. Your organisation should therefore appropriately maintain all records (such as invoices and other supporting documents) related to the THN Pilot for seven (7) years.

9 REVIEW OF DECISIONS

If you have any questions or do not agree with a decision made by PPA in administering your claim for payment, please contact us at support@ppaonline.com.au or on 1800 951 285. We'll check the decision, explain why we made the decision and ensure there aren't any errors. We aim to resolve matters quickly in line with the program rules set out in these guidelines. A discussion explaining a decision is not a formal review.

Formal review

If you still disagree with the outcome, you can ask for a review of the decision. The review will be undertaken by the Department of Health, not PPA, in accordance with the requirements set out in the National Health (Take Home Naloxone Pilot) Special Arrangement 2019. An application for review must be in writing to the Secretary of the Department of Health and importantly, in most circumstances the request for review must be made within 28 days after the decision came to your notice unless a longer period of time is allowed for by the Department of Health.

You can submit your formal request for a review by mail (GPO Box 9848, Canberra ACT 2601, Australia) or by email to s100programs@health.gov.au.

APPENDIX A DATA COLLECTION FOR THE SUPPLY OF NALOXONE TO INDIVIDUALS

The following table indicates which organisations should collect the individual supply data outlined in Appendix A and confirms the method by which this data should be captured and reported.

Organisation	Data capture method	Submit data to:
Community (s90) pharmacies	PPA Portal	PPA
Public and Private Hospital (s94) pharmacies	PPA Portal	PPA
Approved (s92) Medical Practitioners	PPA Portal	PPA
AAS in SA	PPA Portal	PPA
AAS in WA	Data capture spreadsheet	WA MHC
Government AAS in NSW	PPA Portal	PPA

The minimum required data set for each supply is:

- Date of naloxone supply
- Formulations and quantities of naloxone supplied (maximum of two)
- Staff designation (e.g. Pharmacist, Social Worker)
- Whether the individual receiving naloxone consented to their de-identified data being collected and reported for evaluation purposes (see below).

This data is used to determine the appropriate payment rates for S90 and S94 pharmacies, and s92 approved medical practitioners, and is referred to as **payment data** in relation to these organisation types.

You must discuss with the individual whether they consent to provide information for evaluation purposes, using the [Participant Information Statement](#) as a guide.



CONTACT THE SUPPORT CENTRE: 1800 951 285 | support@ppaonline.com.au

TAKE HOME NALOXONE PILOT

If the individual receiving naloxone **consented** to their de-identified data being collected and reported for evaluation purposes, the following additional information must also be recorded (note: this information is only **mandatory for evaluation purposes**, and not for claiming purposes):

- Type of individual (i.e. at risk of experiencing an opioid overdose, or at risk of witnessing one)
- Gender of the individual
- Type of opioid (i.e. prescribed, other source, witness only)
- Whether this was the first time the individual had received naloxone ('initial supply'), or they had received it before ('refill')
- Whether any brief education or advice was provided in relation to naloxone supply.

In addition, the following **optional** information for the evaluation should also be reported for consenting individuals, where available:

- The estimated age range and postcode of the individual
- The reason a refill was required (if applicable)
- Other medications/substances used
- Whether any additional resources were provided in relation to naloxone supply.

State specific requirements

In SA, two additional fields should be collected:

- Whether a voucher was supplied
- Voucher colour.

More information about the process in SA can be found [here](#).

Guidance on how to ask and answer these questions is provided [here](#).

APPENDIX B DATA COLLECTION FOR THE BULK SUPPLY OF NALOXONE TO AAS

Wholesalers and hospital (s94) pharmacies providing bulk supply of naloxone to AAS must supply to the PPA via the portal the following information for payment:

- Name of AAS naloxone supplied to
- Address of AAS naloxone supplied to
- Date of naloxone supply
- Formulations and quantities of naloxone supplied.

Rates of payment vary by organisation type and are summarised at *Section 5, Fees*.

APPENDIX C PREVIOUS SUPPLY FEES

C.1 Fees for supplies between 1 April 2020 and 30 June 2020

Payments under the program are made according to the PBS remuneration rates at the time the supply occurred, not the date the claim was lodged. Pricing for injectable naloxone preparations changed on 1 July 2020. The rates payable for supplies between 1 April 2020 and 30 June 2020 are provided below. Please note Junalox was not available until 27 August 2020 and is therefore not included in the tables below.

Table 8-1: Naloxone supply fees: Community (S90) Pharmacies

Individual Supply (ex GST)	Product
\$48.42	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$41.34	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$45.34	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$45.34	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

Table 8-2: Naloxone supply fees: Public Hospital (S94) Pharmacies

Individual Supply (ex GST)	Bulk Supply (ex GST)	Product
\$36.94	\$34.36	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$29.86	\$27.77	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$33.86	\$31.49	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$33.86	\$31.49	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

TAKE HOME NALOXONE PILOT
Table 8-3: Naloxone supply fees: Private Hospital (S94) Pharmacies

Individual Supply (ex GST)	Bulk Supply (ex GST)	Product
\$44.85	\$34.36	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$37.67	\$27.77	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$41.72	\$31.49	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$41.72	\$31.49	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

Table 8-4: Naloxone supply fees: Approved Medical Practitioners (S92)

Individual Supply (ex GST)	Product
\$48.42	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$41.34	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$45.34	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$45.34	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

Table 8-5: Naloxone supply fees: Manufacturers and Wholesalers

Bulk Supply (ex GST)	Product
\$34.36	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$27.77	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$31.49	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$31.49	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

TAKE HOME NALOXONE PILOT
C.2 Fees for supplies between 1 December 2019 and 31 March 2020

Payments under the program are made according to the PBS remuneration rates at the time the supply occurred, not the date the claim was lodged. Pricing for injectable naloxone preparations changed on 1 April 2020. The rates payable for supplies between 1 December 2019 and 31 March 2020 are provided below.

Please note Junalox was not available until 27 August 2020 and is therefore not included in the tables below

Table 9-6: Previous Naloxone supply fees: Community (S90) Pharmacies

Individual Supply (ex GST)	Product
\$48.42	Nyxoid (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$48.42	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$53.37	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$53.37	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

Table 9-7: Previous Naloxone supply fees: Public Hospital (S94) Pharmacies

Individual Supply (ex GST)	Bulk Supply (ex GST)	Product
\$36.94	\$34.36	Nyxoid (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$36.94	\$34.36	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$41.89	\$38.96	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$41.89	\$38.96	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

TAKE HOME NALOXONE PILOT
Table 9-8: Previous Naloxone supply fees: Private Hospital (S94) Pharmacies

Individual Supply (ex GST)	Bulk Supply (ex GST)	Product
\$44.85	\$34.36	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$44.85	\$34.36	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$49.87	\$38.96	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$49.87	\$38.96	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

Table 9-9: Previous Naloxone supply fees: Approved Medical Practitioners (S92)

Individual Supply (ex GST)	Product
\$48.42	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$48.42	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$53.37	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$53.37	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)

Table 9-10: Previous Naloxone supply fees: Manufacturers and Wholesalers

Bulk Supply (ex GST)	Product
\$34.36	Nyxoïd (naloxone 1.8 mg/actuation nasal spray, 2x1 actuation)
\$34.36	Prenoxad (naloxone hydrochloride 1 mg/mL injection, 2 mL syringe)
\$38.96	Naloxone Juno (naloxone hydrochloride 400 microgram/mL injection, 5x1 mL ampoules)
\$38.96	Naloxone Hydrochloride (DBL) (naloxone hydrochloride 400 microgram/mL injection, 5 x 1 mL ampoules)